SCM
PLSE icon

Segantii Capital Management’s Pulse Biosciences PLSE Stock Holding History

Segantii Capital Management’s Portfolio PLSE Stock Details PLSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-8,100
Closed -$165K – 203
2017
Q1 		$165K Buy
+8,100
New +$110K 0.03% 163

Other funds holding PLSE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
TF
TIAA FSB Jacksonville, Florida $27.6B AUM 14.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Segantii Capital Management's PLSE Position: Q2 2017 in Review

Segantii Capital Management sold out of Pulse Biosciences (PLSE) in Q2 2017, closing a stake of 8,100 shares — an estimated $165K sold.

Segantii Capital Management first reported a position in PLSE in Q1 2017 and held it in 1 quarter. The position peaked at $165K in Q1 2017. 49 funds tracked by Wall St. Rank hold PLSE as of Q2 2017.

  • Segantii Capital Management reported no remaining Pulse Biosciences position as of Q2 2017 after selling out during the quarter.
  • Segantii Capital Management sold 8,100 Pulse Biosciences shares in Q2 2017, an estimated $165K.
  • Segantii Capital Management first reported a position in Pulse Biosciences in Q1 2017 and held it in 1 quarter.
  • Segantii Capital Management's Pulse Biosciences position peaked at $165K in Q1 2017.
  • 49 funds tracked by Wall St. Rank held Pulse Biosciences as of Q2 2017.

Based on Segantii Capital Management's 13F filing for Q2 2017, filed 2 Aug 2017.